Biopharma: Let’s get back to website basics

pharmabacktobasicsPOST SUMMARY: How do users read web content? They don’t.  The truth is, people are going to skim and scan all the lovely content you’ve written, looking for something (a keyword, a header perhaps?) that catches their attention or matches the reason they’re visiting your website in the first place.  Web users spend 80% of their time looking at information above the page fold (meaning, the part of the webpage that’s visible when users first land there). Although users do scroll, they allocate only 20% of their attention below the fold.  Continue reading »

Is big pharma being defined by external forces?

who is big pharmaPOST SUMMARY: Big pharma companies continue to be defined by a myriad of external sources from Congress, questioning high drug prices, to seemingly unorthodox behavior like putting profits over patient safety as in the Boehringer Ingelheim Pradaxa case.  However, biotech companies like Biogen continue to develop and market new drugs by tossing out the big pharma business models and focusing on patients. Continue reading »

Pharma Companies Can’t Ignore Patient Services

Accenture ReportPOST SUMMARY: Patients are exerting more influence than ever on their treatment decisions. Accenture’s survey revealed that patients don’t just want pharmaceutical companies to provide services that complement the products they sell—they expect them to do so. The survey also showed a surprising and significant gap in the services that patients want to get and those that they are receiving. Continue reading »

Dear FDA: Social media guidelines too late

pharma social media too latePOST SUMMARY: While the majority of pharma companies await social media marketing guidelines, consumers are pretty much ignoring brands on the channel.  This means that biopharma marketers are going to have to work extra hard to make social media a viable channel to reach patients and consumers. Continue reading »

Response to Times editorial on drug importation

0126_pills-money_416x4162POST SUMMARY: The NY Times, in an editorial today, left out some key information on compliance and drug costs as they try to support the importation of prescription drugs from outside the U.S..  The editorial suggests that patients should be allowed to purchase prescription drugs from pharmacies outside the U.S. and it suggests that scare” tactics, designed to bring up issues around drug quality, are unwarranted. .   Continue reading »

The skeptical health consumer

i-db2cb78fa4b128fad30b99188c007827-zebraPOST SUMMARY: According to the journal JAMA Internal Medicine fully 37% of those surveyed endorsed the belief that the Food and Drug Administration, under pressure from pharmaceutical companies, is suppressing natural cures for cancer and other diseases, and 31% said they “neither agree nor disagree” with that idea, the researchers found. In addition, one in five said they agreed that physicians and the government “still want to vaccinate children, even though they know these vaccines cause autism and other psychological disorders.” Pharma has a long long way to go to earn the trust of skeptical health consumers. Continue reading »

Higher patient co-pays impact compliance and health

Right about now a lot of people are walking around in shock because of the increased costs of employer sponsored health plans next year.  Not only are they going to have more taken out of their paychecks but, in most cases, they are going to be paying more for doctor visits and medications.  What is the impact to patient health ? Continue reading »

Adverse event reporting online & in social media

screenshot_1664Social media may be the digital revolution causing pharma executives to have sleepless nights about online adverse events, but the phenomenon actually predates the Facebook generation by some time. “Adverse events have been reported by people on the internet ever since there were chat rooms or an ability to post online,” says Joy Liu, a partner at law firm Ropes & Gray, suggesting the issue first reared its head in the early 1990s.  Continue reading »

62% of consumers not interested in hearing from pharma on social media

POST SUMMARY: Do people really want to engage with pharma companies on social media ?  The answer to that is “no” for the majority according to a recent study.  Any engagement is a conversation and all conversations start with trust.  It’s hard to trust an industry that is always in the news for the wrong reasons.  We also have to remember that trust in any “establishment” is low right now as the consumers continue to vent their frustration with a system that, they feel, doesn’t listen to their concerns and needs.

Continue reading »